ORKA-004 + ORKA-001

ORKA-004 + ORKA-001 is an investigational combination therapy being developed by Oruka Therapeutics for the treatment of chronic inflammatory skin diseases, such as plaque psoriasis, and potentially other inflammatory conditions like inflammatory bowel disease (IBD). The combination consists of ORKA-004, a subcutaneously administered, half-life extended monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A), and ORKA-001, a subcutaneously administered, half-life extended monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23p19). By targeting both the TL1A and IL-23p19 pathways, the combination aims to provide synergistic therapeutic efficacy with infrequent dosing. Phase 2 combination trials are planned to begin in 2027.